Abstract
This essay characterizes regulatory controversy through communicative practices that bridge the technical and public spheres of argument. The case of Procter & Gamble's efforts to gain approval and consumers for the fat substitute olestra, opposed by the Center for Science in the Public Interest, serves as a vehicle for exploring the nature of regulatory controversy and the interdependence of public and technical argument. Out-law discourse, a discourse of dissent, ignores conventional standards of argument and is invited in regulatory controversy when extant arenas for argument are not flexible enough to accommodate dissent. This out-law discourse is explored through the tactics of objection and counteranalysis, and the essay concludes that regulatory controversy actually places a greater burden on corporate actors than on their out-law opponents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.